Closing the Genomic Gap: Strategies to Enhance Biobanking Participation Among Black Women with Endometrial Cancer

Highlights

• Black women experience disproportionately high mortality rates from endometrial cancer (EC), yet remain significantly underrepresented in the biobanks necessary to study the molecular drivers of these disparities.
• The SISTER Study demonstrates that “Return of Value” (ROV)—specifically sharing genetic and lifestyle risk results—is a more potent motivator for participation than monetary compensation.
• Trust, transparency, and a commitment to family and community health are the primary drivers for Black EC survivors when deciding to engage in translational research.
• A set of 14 community-validated recommendations provides a framework for researchers to design more inclusive and ethical biobanking protocols.

Background

Endometrial cancer (EC) is one of the few malignancies in the United States with both increasing incidence and rising mortality. However, the burden of this disease is not shared equally. Black women are more likely to be diagnosed with aggressive histological subtypes (such as serous or clear cell carcinomas), present at advanced stages, and experience significantly worse survival outcomes compared to their white counterparts, even when accounting for stage and treatment access.

To address these inequities, translational research must delve into the molecular and social determinants of the EC disparity. Biobanking—the systematic collection of biospecimens and associated clinical data—is the cornerstone of this effort. Despite its importance, historical medical mistrust, systemic barriers, and a lack of community-centric recruitment strategies have led to a profound underrepresentation of Black individuals in genomic databases. This “genomic gap” risks creating a future where precision medicine interventions are less effective for the populations most affected by the disease.

Key Content

The Biobanking Gap and the Molecular Basis of Disparity

Recent advances in the Molecular Classification of Endometrial Cancer (e.g., Proactive Molecular Risk Classifier for Endometrial Cancer or ProMisE) have transformed our understanding of the disease. However, much of the foundational data for these classifications were derived from cohorts with limited racial diversity. This lack of representation limits the generalizability of genomic markers and therapeutic targets. Recent study by Salehipour et al. (2026) highlights that enhancing engagement is not merely a matter of recruitment logistics but requires a fundamental shift in how research value is returned to participants.

Methodological Innovation: The SISTER Study

Leveraging “The Social Interventions for Support during Treatment for Endometrial Cancer and Recurrence” (SISTER) Study, researchers utilized a community-engaged mixed-methods approach. This included a survey of 50 Black EC survivors and focus groups with 13 participants. Unlike traditional top-down research models, this study co-developed its recommendations with a community advisory council, ensuring that the findings were grounded in the lived experiences of Black women.

Evidence-Based Prioritization of Return of Value (ROV)

One of the most significant findings of the study was the hierarchy of Return of Value (ROV). Participants were asked to rank factors that would influence their decision to participate in a biobank:

• Genetic and Lifestyle Insights: Participants rated information about how genetics and lifestyle factors influence disease risk as the highest priority. There is a profound desire among survivors to understand the “why” behind their diagnosis.
• Financial Incentives: Interestingly, monetary compensation was rated significantly lower than the return of health-related information. This suggests that while compensation is important for covering costs (transportation, time), it is not the primary driver of altruistic participation in this demographic.
• Novel ROV Items: Three new priorities emerged: a desire for updated EC knowledge, a commitment to improving family health outcomes, and a broader commitment to community well-being.

Thematic Insights: Trust, Transparency, and Altruism

Focus group analysis revealed that the willingness to donate biospecimens is inextricably linked to the perceived trustworthiness of the institution. Transparency regarding what happens to the samples, who has access to the data, and how the results will benefit the Black community at large were recurring themes. This aligns with a shift toward “solidarity-based” research models where participants are viewed as active stakeholders rather than passive donors.

Recommendations for Clinical Research Conduct

The study culminated in 14 specific recommendations for researchers aiming to engage underrepresented groups in biobanking. These include:

1. Establishment of ROV Protocols: Researchers must have a clear plan for returning clinically relevant results to participants.
2. Community Partnership: Engaging community leaders early in the study design phase rather than just at the recruitment phase.
3. Cultural Humility: Training research staff in the historical context of medical exploitation and practicing active listening.
4. Clear Communication: Using non-stigmatizing language and clear visualizations to explain the biobanking process.

Expert Commentary

The work of Salehipour and colleagues represents a critical pivot in gynecologic oncology research. For too long, the narrative surrounding the underrepresentation of Black women in research focused on “recruitment failures” or participant “hesitancy.” This study reframes the issue as a failure of the research infrastructure to provide meaningful value and maintain transparency.

From a clinical standpoint, the high interest in genetic and lifestyle data underscores a major opportunity for integration between research and clinical care. If biobanks can act as a bridge—returning information that helps a survivor’s family members assess their own risk—participation becomes an act of familial protection. However, this also raises ethical questions regarding the infrastructure needed to provide genetic counseling for returned results, which must be addressed at the institutional level.

Furthermore, the finding that monetary compensation is a secondary motivator should not be misinterpreted as a reason to underpay participants. Rather, it emphasizes that for this population, the “currency” of trust and knowledge is more valuable than a one-time payment. Researchers must invest in long-term relationships with the communities they serve to overcome the legacy of medical racism.

Conclusion

Enhancing biobanking participation among Black women with endometrial cancer is a prerequisite for achieving health equity in gynecologic oncology. By prioritizing the return of health-related value, fostering transparent communication, and recognizing the altruistic motivations of survivors, the research community can build the diverse datasets required for the next generation of precision medicine. These community-validated recommendations should serve as a blueprint for future study designs, ensuring that the benefits of translational science are accessible to all.

References

• Salehipour D, Tadess B, Moore A, et al. Enhancing engagement in biobanking research among Black women with endometrial cancer. Gynecologic oncology. 2026;208:32-40. PMID: 41833227.
• Clevenger L, et al. Disparities in endometrial cancer: The role of molecular subtyping. Trends in Cancer. 2023;9(11):912-925.
• Doll KM, et al. The SISTER Study: A community-engaged approach to endometrial cancer disparities. J Clin Oncol. 2022;40(16_suppl):e18500.